Riti Forest

Researchers are evaluating the effectiveness and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab combined with bevacizumab in people with advanced hepatocellular carcinoma (HCC) who cannot undergo curative or localized treatments. This Phase III global study includes a safety lead-in period to assess the tolerability of rilvegostomig with bevacizumab and tremelimumab before the randomized treatment phase begins. Participants receive intravenous treatments with rilvegostomig, bevacizumab, and tremelimumab in one group, while another group receives atezolizumab with bevacizumab. The study has two parts: a safety lead-in where all participants get rilvegostomig, bevacizumab, and tremelimumab to check safety, followed by a randomized period comparing the three treatment arms. The treatments are given as first-line therapy for advanced HCC. During the study, participants are regularly monitored through imaging and lab tests to measure tumor response and organ function. Researchers track overall survival up to about six years to evaluate treatment effectiveness. Safety and tolerability are closely observed throughout, with ongoing assessments to ensure participant well-being during treatment and follow-up periods.